UPDATE: Eagle Pharmaceuticals (EGRX) Reports Q4 EPS of 48c

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q4 EPS of $0.48 vs the analyst estimate of $0.49. Revenue for the quarter came in at $48.3 million versus the consensus estimate of $49.07 million.

2020 Expense Guidance

• R&D spend in 2020, on a non-GAAP basis, is expected to be $46-$50 million, as compared to $31.1 million in 2019.
• SG&A spend in 2020, on a non-GAAP basis, is expected to be $61-$64 million, as compared to $56.4 million in 2019.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat